Literature DB >> 18285711

Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals.

Phyllis C Tien1, Donald P Kotler, E Turner Overton, Cora E Lewis, David Rimland, Peter Bacchetti, Rebecca Scherzer, Barbara Gripshover.   

Abstract

BACKGROUND: The association of fat distribution with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations is not well-defined in HIV-infected individuals. Obesity is associated with hepatic steatosis, and ALT is a marker of steatosis in the general population.
METHODS: Cross-sectional analysis of 1119 HIV-infected and 284 control subjects. Hepatitis C virus (HCV) RNA testing determined HCV infection. Magnetic resonance imaging measured regional adipose tissue volume.
RESULTS: After adjustment for demographic and lifestyle factors, visceral adipose tissue (VAT) was positively associated with ALT in HIV/HCV-coinfected subjects (+9.8%, 95% confidence interval [CI]: 2.8 to 17.6), HIV-monoinfected subjects (+8.0%, 95% CI: 4.2 to 12.1), and controls (+5.9%, 95% CI: 2.0 to 10.1). In contrast, lower trunk subcutaneous adipose tissue (SAT) was negatively associated with ALT in HIV/HCV-coinfected subjects (-14.3%, 95% CI: -24.7 to -4.2) and HIV-monoinfected subjects (-11.9%, 95% CI: -18.4 to -5.3); there was a trend toward an association in controls (-7.1%, 95% CI: -22.7 to 5.9). Estimated associations between regional adipose tissue and AST were small and did not reach statistical significance.
CONCLUSIONS: More VAT and less lower trunk SAT are associated with elevated ALT, which likely reflects the presence of steatosis. There was little association with AST. HCV infection and having more VAT or less lower trunk SAT are independently associated with elevated ALT in HIV infection. Study regarding the association between VAT, trunk SAT, HCV, and progression of steatosis and fibrosis is needed in HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285711      PMCID: PMC2776053          DOI: 10.1097/QAI.0b013e3181685700

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  41 in total

1.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

Authors:  M S Sulkowski; D L Thomas; R E Chaisson; R D Moore
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

2.  Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.

Authors:  M den Brinker; F W Wit; P M Wertheim-van Dillen; S Jurriaans; J Weel; R van Leeuwen; N G Pakker; P Reiss; S A Danner; G J Weverling; J M Lange
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

3.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.

Authors:  L E Adinolfi; M Gambardella; A Andreana; M F Tripodi ; R Utili; G Ruggiero
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

4.  Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

Authors:  Mark S Sulkowski; David L Thomas; Shruti H Mehta; Richard E Chaisson; Richard D Moore
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

5.  Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection.

Authors:  Antonio Aceti; Caterina Pasquazzi; Barbara Zechini; Carlo De Bac
Journal:  J Acquir Immune Defic Syndr       Date:  2002-01-01       Impact factor: 3.731

6.  Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy.

Authors:  D C Mynarcik; M A McNurlan; R T Steigbigel; J Fuhrer; M C Gelato
Journal:  J Acquir Immune Defic Syndr       Date:  2000-12-01       Impact factor: 3.731

7.  Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Authors:  E Martínez; J L Blanco; J A Arnaiz; J B Pérez-Cuevas; A Mocroft; A Cruceta; M A Marcos; A Milinkovic; M A García-Viejo; J Mallolas; X Carné; A Phillips; J M Gatell
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

Review 8.  Lipodystrophies.

Authors:  A Garg
Journal:  Am J Med       Date:  2000-02       Impact factor: 4.965

9.  Updated definitions of healthy ranges for serum alanine aminotransferase levels.

Authors:  Daniele Prati; Emanuela Taioli; Alberto Zanella; Emanuela Della Torre; Sonia Butelli; Emanuela Del Vecchio; Luciana Vianello; Francesco Zanuso; Fulvio Mozzi; Silvano Milani; Dario Conte; Massimo Colombo; Girolamo Sirchia
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

10.  The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics.

Authors:  Phyllis C Tien; Constance Benson; Andrew R Zolopa; Stephen Sidney; Dennis Osmond; Carl Grunfeld
Journal:  Am J Epidemiol       Date:  2006-03-08       Impact factor: 4.897

View more
  6 in total

Review 1.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

2.  Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.

Authors:  Lindsay T Fourman; Natalia Czerwonka; Meghan N Feldpausch; Julian Weiss; Jean-Claude Mamputu; Julian Falutz; Josée Morin; Christian Marsolais; Takara L Stanley; Steven K Grinspoon
Journal:  AIDS       Date:  2017-10-23       Impact factor: 4.177

3.  Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons.

Authors:  Todd T Brown; Shruti H Mehta; Catherine Sutcliffe; Yvonne Higgins; Michael S Torbenson; Richard D Moore; David L Thomas; Mark S Sulkowski
Journal:  AIDS       Date:  2010-03-27       Impact factor: 4.177

4.  Association of HIV infection, hepatitis C virus infection, and metabolic factors with liver stiffness measured by transient elastography.

Authors:  M Rami Bailony; Rebecca Scherzer; Gregory Huhn; Michael W Plankey; Marion G Peters; Phyllis C Tien
Journal:  J Infect Dis       Date:  2013-07-30       Impact factor: 5.226

5.  Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection.

Authors:  Rebecca Scherzer; Steven B Heymsfield; David Rimland; William G Powderly; Phyllis C Tien; Peter Bacchetti; Michael G Shlipak; Carl Grunfeld
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

6.  Differential relationships of hepatic and epicardial fat to body composition in HIV.

Authors:  Lindsay T Fourman; Michael T Lu; Hang Lee; Kathleen V Fitch; Travis R Hallett; Jakob Park; Natalia Czerwonka; Julian Weiss; Takara L Stanley; Janet Lo; Steven K Grinspoon
Journal:  Physiol Rep       Date:  2017-10-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.